Asia Pacific Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity

About the Report

About the Report

Asia Pacific digital biomarkers market will grow by 34.7% annually with a total addressable market cap of USD 35.52 billion over 2020-2030 owing to the rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic.

Highlighted with 38 tables and 66 figures, this 143-page report Asia Pacific Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Country.

Based on System Component, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Data Collection Tools

Digital Platforms

Mobile Apps

Desktop-based Software

Wearables

Biosensors

Data Integration Systems

Based on Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cardiovascular Diseases

Neurodegenerative Disorders

Parkinson's Disease

Multiple Sclerosis

Alzheimer's Disease

Sleep and Movement Diseases

Psychiatric Disorders

Chronic Pain

Gastrointestinal Diseases

Diabetes

Respiratory Conditions

Other Diseases

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Wellness

Disease Diagnosis

Personalised Medication

Drug Discovery and Development

Based on Development Status, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Novel Digital Biomarkers

Original Digital Biomarkers

Approved Digital Biomarkers

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Biopharmaceutical Companies & Labs

Healthcare Providers

Insurance Payers

Geographically, the following national/local markets are fully investigated:

Japan

China

South Korea

Australia

India

Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific digital biomarkers market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Actigraph LLC

Akili Interactive Labs

AliveCor Inc

Altoida Inc

Amgen Inc

Bayer AG

Biogen Inc

Cambridge Cognition Plc

Eli Lilly and Company

Evidation Health, Inc.

F. Hoffmann-La Roche Ltd

Fitbit Inc

GlaxoSmithKline Plc

Happify Health

Human API

IXICO Plc

Koninklijke Philips N.V.

Medical Care Corporation

Medopad Ltd

Mindstrong Health

Neurotrack Technology, Inc

Novartis International AG

Pfizer Inc.

Quanterix Corporation

Sanofi S.A.

The Takeda Pharmaceuticals Company Limited

Verily Life Sciences

Winterlight Labs Inc.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Products


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

Actigraph LLC

Akili Interactive Labs

AliveCor Inc

Altoida Inc

Amgen Inc

Bayer AG

Biogen Inc

Cambridge Cognition Plc

Eli Lilly and Company

Evidation Health, Inc.

F. Hoffmann-La Roche Ltd

Fitbit Inc

GlaxoSmithKline Plc

Happify Health

Human API

IXICO Plc

Koninklijke Philips N.V.

Medical Care Corporation

Medopad Ltd

Mindstrong Health

Neurotrack Technology, Inc

Novartis International AG

Pfizer Inc.

Quanterix Corporation

Sanofi S.A.

The Takeda Pharmaceuticals Company Limited

Verily Life Sciences

Winterlight Labs Inc.

Table of Contents

Table of Contents

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 14

1.2.6 Market Size/Share Estimation 15

1.2.7 Research Limitations 16

1.3 Executive Summary 17

2 Market Overview and Dynamics 20

2.1 Market Size and Forecast 20

2.1.1 Impact of COVID-19 on the Market 25

2.2 Major Growth Drivers 27

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 37

2.5 Porter's Fiver Forces Analysis 41

3 Segmentation of Asia Pacific Market by System Component 45

3.1 Market Overview by System Component 45

3.2 Data Collection Tools 47

3.2.1 Digital Platforms 49

3.2.2 Mobile Apps 50

3.2.3 Desktop-based Software 51

3.2.4 Wearables 52

3.2.5 Biosensors 53

3.3 Data Integration Systems 54

4 Segmentation of Asia Pacific Market by Therapeutic Area 55

4.1 Market Overview by Therapeutic Area 55

4.2 Cardiovascular Diseases 57

4.3 Neurodegenerative Disorders 58

4.3.1 Parkinson's Disease 60

4.3.2 Multiple Sclerosis 61

4.3.3 Alzheimer's Disease 62

4.4 Sleep and Movement Diseases 63

4.5 Psychiatric Disorders 64

4.6 Chronic Pain 65

4.7 Gastrointestinal Diseases 66

4.8 Diabetes 67

4.9 Respiratory Conditions 68

4.10 Other Diseases 69

5 Segmentation of Asia Pacific Market by Application 70

5.1 Market Overview by Application 70

5.2 Wellness 72

5.3 Disease Diagnosis 73

5.4 Personalised Medication 74

5.5 Drug Discovery and Development 75

6 Segmentation of Asia Pacific Market by Development Status 77

6.1 Market Overview by Development Status 77

6.2 Novel Digital Biomarkers 80

6.3 Original Digital Biomarkers 81

6.4 Approved Digital Biomarkers 82

7 Segmentation of Asia Pacific Market by End User 83

7.1 Market Overview by End User 83

7.2 Biopharmaceutical Companies & Labs 85

7.3 Healthcare Providers 86

7.4 Insurance Payers 87

8 Asia-Pacific Market 2019-2030 by Country 88

8.1 Overview of Asia-Pacific Market 88

8.2 Japan 91

8.3 China 94

8.4 Australia 96

8.5 India 98

8.6 South Korea 100

8.7 Rest of APAC Region 102

9 Competitive Landscape 104

9.1 Overview of Key Vendors 104

9.2 New Product Launch, Partnership, Investment, and M&A 107

9.3 Company Profiles 108

Actigraph LLC 108

Akili Interactive Labs 110

AliveCor Inc 111

Altoida Inc 112

Amgen Inc 113

Bayer AG 114

Biogen Inc 115

Cambridge Cognition Plc 116

Eli Lilly and Company 117

Evidation Health, Inc. 118

F. Hoffmann-La Roche Ltd 119

Fitbit Inc 120

GlaxoSmithKline Plc 121

Happify Health 122

Human API 123

IXICO Plc 124

Koninklijke Philips N.V. 125

Medical Care Corporation 126

Medopad Ltd 127

Mindstrong Health 128

Neurotrack Technology, Inc 129

Novartis International AG 130

Pfizer Inc. 131

Quanterix Corporation 132

Sanofi S.A. 133

The Takeda Pharmaceuticals Company Limited 134

Verily Life Sciences 135

Winterlight Labs Inc. 136

10 Investing in Asia Pacific Market: Risk Assessment and Management 137

10.1 Risk Evaluation of Asia Pacific Market 137

10.2 Critical Success Factors (CSFs) 140

Related Reports and Products 143


List of Figure

Figure 1. Research Method Flow Chart 11

Figure 2. Breakdown of Primary Research 13

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15

Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17

Figure 5. Asia Pacific Digital Biomarkers Market, 2019-2030, USD mn 20

Figure 6. Category and Relationship of Traditional Biomarkers and Digital Biomarkers 21

Figure 7. Benefits and Challenges of Digital Biomarkers 23

Figure 8. Asia Pacific Biomarkers Market, 2019-2030, USD mn 24

Figure 9. Share of Digital Biomarkers in Total Biomarkers Market, 2019-2030 24

Figure 10. Impact of COVID-19 on Business 25

Figure 11. Primary Drivers and Impact Factors of Asia Pacific Digital Biomarkers Market 27

Figure 12. World 5G Traffic, 2019-2030, EB/year 30

Figure 13. Primary Restraints and Impact Factors of Asia Pacific Digital Biomarkers Market 32

Figure 14. Data Security Risk in Various User Groups of Digital Biomarkers 35

Figure 15. Pathway to Regulatory Approval of Digital Biomarkers 36

Figure 16. Investment Opportunity Analysis 38

Figure 17. Porter's Fiver Forces Analysis of Asia Pacific Digital Biomarkers Market 41

Figure 18. Breakdown of Asia Pacific Digital Biomarkers Market by System Component, 2019-2030, % of Revenue 46

Figure 19. Asia Pacific Addressable Market Cap in 2020-2030 by System Component, Value (USD mn) and Share (%) 46

Figure 20. Asia Pacific Digital Biomarkers Market: Data Collection Tools, 2019-2030, USD mn 47

Figure 21. Asia Pacific Digital Biomarkers Market: Digital Platforms, 2019-2030, USD mn 49

Figure 22. Asia Pacific Digital Biomarkers Market: Mobile Apps, 2019-2030, USD mn 50

Figure 23. Asia Pacific Digital Biomarkers Market: Desktop-based Software, 2019-2030, USD mn 51

Figure 24. Asia Pacific Digital Biomarkers Market: Wearables, 2019-2030, USD mn 52

Figure 25. Asia Pacific Digital Biomarkers Market: Biosensors, 2019-2030, USD mn 53

Figure 26. Asia Pacific Digital Biomarkers Market: Data Integration Systems, 2019-2030, USD mn 54

Figure 27. Breakdown of Asia Pacific Digital Biomarkers Market by Therapeutic Area, 2019-2030, % of Sales Revenue 56

Figure 28. Asia Pacific Addressable Market Cap in 2020-2030 by Therapeutic Area, Value (USD mn) and Share (%) 56

Figure 29. Asia Pacific Digital Biomarkers Market: Cardiovascular Diseases, 2019-2030, USD mn 57

Figure 30. Asia Pacific Digital Biomarkers Market: Neurodegenerative Disorders, 2019-2030, USD mn 58

Figure 31. Asia Pacific Digital Biomarkers Market: Parkinson's Disease, 2019-2030, USD mn 60

Figure 32. Asia Pacific Digital Biomarkers Market: Multiple Sclerosis, 2019-2030, USD mn 61

Figure 33. Asia Pacific Digital Biomarkers Market: Alzheimer's Disease, 2019-2030, USD mn 62

Figure 34. Asia Pacific Digital Biomarkers Market: Sleep and Movement Diseases, 2019-2030, USD mn 63

Figure 35. Asia Pacific Digital Biomarkers Market: Psychiatric Disorders, 2019-2030, USD mn 64

Figure 36. Asia Pacific Digital Biomarkers Market: Chronic Pain, 2019-2030, USD mn 65

Figure 37. Asia Pacific Digital Biomarkers Market: Gastrointestinal Diseases, 2019-2030, USD mn 66

Figure 38. Asia Pacific Digital Biomarkers Market: Diabetes, 2019-2030, USD mn 67

Figure 39. Asia Pacific Digital Biomarkers Market: Respiratory Conditions, 2019-2030, USD mn 68

Figure 40. Asia Pacific Digital Biomarkers Market: Other Diseases, 2019-2030, USD mn 69

Figure 41. Breakdown of Asia Pacific Digital Biomarkers Market by Application, 2019-2030, % of Sales Revenue 71

Figure 42. Asia Pacific Addressable Market Cap in 2020-2030 by Application, Value (USD mn) and Share (%) 71

Figure 43. Asia Pacific Digital Biomarkers Market: Wellness, 2019-2030, USD mn 72

Figure 44. Asia Pacific Digital Biomarkers Market: Disease Diagnosis, 2019-2030, USD mn 73

Figure 45. Asia Pacific Digital Biomarkers Market: Personalised Medication, 2019-2030, USD mn 74

Figure 46. Asia Pacific Digital Biomarkers Market: Drug Discovery and Development, 2019-2030, USD mn 75

Figure 47. Classification of Digital Biomarkers by Development Status 77

Figure 48. Breakdown of Asia Pacific Digital Biomarkers Market by Development Status, 2019-2030, % of Revenue 79

Figure 49. Asia Pacific Addressable Market Cap in 2020-2030 by Development Status, Value (USD mn) and Share (%) 79

Figure 50. Asia Pacific Digital Biomarkers Market: Novel Digital Biomarkers, 2019-2030, USD mn 80

Figure 51. Asia Pacific Digital Biomarkers Market: Original Digital Biomarkers, 2019-2030, USD mn 81

Figure 52. Asia Pacific Digital Biomarkers Market: Approved Digital Biomarkers, 2019-2030, USD mn 82

Figure 53. Breakdown of Asia Pacific Digital Biomarkers Market by End User, 2019-2030, % of Revenue 84

Figure 54. Asia Pacific Addressable Market Cap in 2020-2030 by End User, Value (USD mn) and Share (%) 84

Figure 55. Asia Pacific Digital Biomarkers Market: Biopharmaceutical Companies & Labs, 2019-2030, USD mn 85

Figure 56. Asia Pacific Digital Biomarkers Market: Healthcare Providers, 2019-2030, USD mn 86

Figure 57. Asia Pacific Digital Biomarkers Market: Insurance Payers, 2019-2030, USD mn 87

Figure 58. Breakdown of APAC Digital Biomarkers Market by Country, 2019 and 2030, % of Revenue 89

Figure 59. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value (USD mn) and Share (%) 90

Figure 60. Digital Biomarkers Market in Japan, 2019-2030, USD mn 92

Figure 61. Digital Biomarkers Market in China, 2019-2030, USD mn 94

Figure 62. Digital Biomarkers Market in Australia, 2019-2030, USD mn 96

Figure 63. Digital Biomarkers Market in India, 2019-2030, USD mn 98

Figure 64. Digital Biomarkers Market in South Korea, 2019-2030, USD mn 100

Figure 65. Digital Biomarkers Market in Rest of APAC, 2019-2030, USD mn 102

Figure 66. Growth Stage of Asia Pacific Digital Biomarkers Industry over the Forecast Period 104


List of Table

Table 1. Snapshot of Asia Pacific Digital Biomarkers Market, 2019-2030 18

Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples 22

Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030 30

Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year 31

Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year 31

Table 6. Current Challenges of Digital Biomarkers in Medical Settings 34

Table 7. Main Product Trends and Market Opportunities in Asia Pacific Digital Biomarkers Market 37

Table 8. Asia Pacific Digital Biomarkers Market by System Component, 2019-2030, USD mn 45

Table 9. Asia Pacific Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, USD mn 48

Table 10. Asia Pacific Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 55

Table 11. Asia Pacific Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, USD mn 59

Table 12. Asia Pacific Digital Biomarkers Market by Application, 2019-2030, USD mn 70

Table 13. Asia Pacific Digital Biomarkers Market by Development Status, 2019-2030, USD mn 78

Table 14. Asia Pacific Digital Biomarkers Market by End User, 2019-2030, USD mn 83

Table 15. APAC Digital Biomarkers Market by Country, 2019-2030, USD mn 89

Table 16. Japan Digital Biomarkers Market by System Component, 2019-2030, USD mn 93

Table 17. Japan Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 93

Table 18. Japan Digital Biomarkers Market by End User, 2019-2030, USD mn 93

Table 19. China Digital Biomarkers Market by System Component, 2019-2030, USD mn 95

Table 20. China Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 95

Table 21. China Digital Biomarkers Market by End User, 2019-2030, USD mn 95

Table 22. Australia Digital Biomarkers Market by System Component, 2019-2030, USD mn 97

Table 23. Australia Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 97

Table 24. Australia Digital Biomarkers Market by End User, 2019-2030, USD mn 97

Table 25. India Digital Biomarkers Market by System Component, 2019-2030, USD mn 99

Table 26. India Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 99

Table 27. India Digital Biomarkers Market by End User, 2019-2030, USD mn 99

Table 28. South Korea Digital Biomarkers Market by System Component, 2019-2030, USD mn 101

Table 29. South Korea Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 101

Table 30. South Korea Digital Biomarkers Market by End User, 2019-2030, USD mn 101

Table 31. Digital Biomarkers Market in Rest of APAC by Country, 2019-2030, USD mn 103

Table 32. Actigraph LLC: Company Snapshot 108

Table 33. Actigraph LLC: Business Segmentation 108

Table 34. Actigraph LLC: Product Portfolio 109

Table 35. Actigraph LLC: Revenue, 2016-2018, USD mn 109

Table 36. Actigraph LLC: Recent Developments 109

Table 37. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030 138

Table 38. Critical Success Factors and Key Takeaways 141

You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022

What Our Clients Say About Us